Treatment-Resistant Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Treatment-Resistant Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Treatment- Resistant Depression Treatment Market

The treatment- resistant depression treatment market size was valued at USD 1.71 billion in 2023, and the market is now projected to grow from USD 1.95 billion in 2024 to USD 4.06 billion by 2032, exhibiting a CAGR of 11.0% during the forecast period of 2024-2032.

Pandemic has appreciably improved demand for healthcare, specifically in treating psychiatric issues. Treatment-resistant despair remedy has surged because of lockdown measures and extended patient suicide risks. The pandemic has additionally reduced stigma surrounding intellectual health remedy, boosting demand. Market players and government-funded research institutes have initiated drug development tasks to cope with this problem. This has led to the introduction of novel remedies and multiplied revenue for tablets, along with Lexapro, which noticed a 9.7% boom in 2020.

The increasing burden of remedy-resistant depression, a condition where patients have no longer responded to two different antidepressants for at the least six weeks, is a full-size driving force of marketplace growth. This disorder is connected to rising healthcare expenses, which stress healthcare systems in exceptional international locations. The range in healthcare settings and access to amazing offerings make contributions to the demand for powerful therapeutic measures. This focus, specifically in emerging countries, is expected to reinforce demand for drugs and foster overall market boom.

The growing incidence of despair and the need for early analysis and control have brought about extended consciousness of to be had remedy alternatives. Market players are that specialize in developing novel routes of administration for tablets, such as intranasal esketamine. Traditional antidepressants take 4-6 weeks to expose results, but intranasal esketamine has proven higher outcomes in hours. Novartis Pharmaceuticals' MIJ821 verified a good-sized discount in depressive episodes in 24 hours of weekly intravenous management. This research and improvement are anticipated to enhance drug demand and treatment- resistant depression treatment market growth.

Comprehensive Analysis of Treatment- Resistant Depression Treatment Market

The treatment-resistant depression treatment market is divided into antidepressants, antipsychotics, and other drugs. The antidepressants segment is expected to dominate due to the increasing prevalence of this mood disorder and the demand for antidepressant drugs. The N-methyl-D-aspartate (NMDA) segment is predicted to grow at the highest rate due to increasing research studies and FDA approvals. The market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Hospital pharmacies are expected to grow at a significant CAGR due to the need for a prescription from a medical professional and increasing public sector investment in healthcare infrastructure in developing countries. Drug shops and retail pharmacies are anticipated to extend at a slight CAGR due to growing affected person demand, extended drug stores and retail pharmacies, and government capitalization. Online pharmacies are anticipated to grow at the highest CAGR because of the surging launch of on-line pharmacies and growing funding in on-line pharmacies.

The North America region lead the treatment- resistant depression treatment market share by benefitting a market size of USD 0.94 billion in 2023 due to an growing patient population with treatment-resistant depressive sickness, expanded treatment resistance at American Psychiatric Association-linked institutions, and the growing variety of pointers and drug approvals within the place.

Eli Lilly, Pfizer, and GlaxoSmithKline are leading the market in remedy-resistant melancholy remedy, with sturdy brand presence and drug services in antipsychotics and antidepressants. They are investing in research and improvement to release superior drug instructions. They are also specializing in tactical mergers with different agencies and studies corporations to develop powerful treatment alternatives. Other players in the marketplace consist of AbbVie, Janssen Global Services, H. Lundbeck, Sandoz International, Otsuka Pharmaceutical, Par Pharmaceutical, and AstraZeneca.

GH Research obtained initial approvals for the Phase 2b trial of GHOOI in TRD (GHOOI -TRD-201) in January 2023, with the trial expected to start in QI 2023.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Unit Value (USD billion)

Growth Rate CAGR of 11.0% from 2023-2030

Segmentation By Drug Type

N-methyl-D-aspartate (NMDA)

Antidepressants

Antipsychotics

Others

By Distribution Channel

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Geography

North America (U.S. and Canada)

Europe (Germany, U.K., France, Italy, Spain, and the Rest of Europe)

Asia Pacific (China, India, Japan, Australia, and the Rest of Asia Pacific)

Rest of the World


Please Note: It will take 5-6 business days to complete the report upon order confirmation.